Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270059 · ClinicalTrials.gov registry record · Phase 2
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
A Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03270059: Recruiting Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm, sponsored by OHSU Knight Cancer Institute.
NCT03270059 is a Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 150 participants, above the 85-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03270059, a Phase 2 study of Metastatic Malignant Neoplasm in the Brain and Central Nervous System Neoplasm, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
Primary Outcome
Primary analysis will use the average score of the two readers. The mean difference and the associated 95% confidence interval (CI) between the two groups will be estimated using a linear regression model. Equivalence will be claimed if the 95% CI does not include 0.4 on either side (equivalence margin is 0.4).
Conditions Studied
Interventions
- DRUG Ferumoxytol
- PROCEDURE Magnetic Resonance Imaging
- DRUG Gadolinium
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
What NCT03270059 shows while recruiting
NCT03270059 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 85-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (76% higher).
The record links to 3 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 3 interventions - of which Ferumoxytol is the first listed.
NCT03270059 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03270059 about?
NCT03270059 is a clinical study titled "Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System". This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervou...
What is the current status of trial NCT03270059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-10-06. Estimated completion is 2028-12-15.
What conditions does trial NCT03270059 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Central Nervous System Neoplasm, Cranial Nerve Disorder.
What interventions are being tested in trial NCT03270059?
The interventions under investigation include: Ferumoxytol (DRUG), Magnetic Resonance Imaging (PROCEDURE), Gadolinium (DRUG).
Who is sponsoring clinical trial NCT03270059?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03270059 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03270059's enrollment target sits among peer trials
150 9th of 43 higher than 35 of 43 other Metastatic Malignant Neoplasm in the Brain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm in the Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
RECRUITING · Phase 2
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RECRUITING · Phase 2
-
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI